Answers are grounded in this paper and cite their sources.
Cardiac arrhythmias are a major cause of morbidity and mortality.Cardiac rhythm management devices (CRMDs) are used to diagnose and treat heart rhythm abnormalities.Many prospective randomized trials over the past decade have established the efficacy of CRMD therapy in reducing all-cause mortality and improving the quality of life.The manufacturer of every device provides its longevity in its technical characteristics, which are, as studies show, shorter in practice.Patients are concerned about the replacement procedure due to the risk of the procedure and other socioeconomic reasons.The longer the longevity of the devices, the better for the patients, the payers, the doctors and the health care systems.Given the recently redefined term of health technology assessment on a European level, a new regulatory framework has been proposed.Its intention is that, across different healthcare systems, the upfront costs and the reimbursement costs of these devices should be proportional to their longevity.
No takes yet. Share an insight, caveat, or question.
John Fanourgiakis (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: